Beroctocog alfa

DB14473ApprovedInvestigationalProtein Based TherapiesHuman Antihemophilic Factors

Beroctocog alfa is indicated for the prevention and control of bleeding in patients with hemophilia A or acquired Factor VIII (FVIII) deficiency. It is also indicated for surgical/invasive procedures in...

Mechanism
Curator reviewed
Primary indication
Beroctocog alfa is indicated for the prevention and control of bleeding in patients with hemophilia A or acquired Factor VIII (FVIII) deficiency.Curator reviewed · 6 structured indications
First approval
United States, 1978
Also known as
Factor VIII
Brand names
  • Alphanate

Resolves to

Compound
UNII17RNR4H479CAS9001-27-8
Clinical / RWD
RxNorm4257
Targets
P00451F8

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
92Drug interactionsStructured to mechanism, not free text
Sign in
42Clinical trialsPhase, status and sponsor resolved per trial
Sign in
6Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
57Marketed productsAcross 6 countries and 18 labellers
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Beroctocog alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In